Terms: = Leukemia AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Clinical Outcome
95 results:
1. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial.
Schubert ML; Schmitt A; Hückelhoven-Krauss A; Neuber B; Kunz A; Waldhoff P; Vonficht D; Yousefian S; Jopp-Saile L; Wang L; Korell F; Keib A; Michels B; Haas D; Sauer T; Derigs P; Kulozik A; Kunz J; Pavel P; Laier S; Wuchter P; Schmier J; Bug G; Lang F; Gökbuget N; Casper J; Görner M; Finke J; Neubauer A; Ringhoffer M; Wolleschak D; Brüggemann M; Haas S; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
J Hematol Oncol; 2023 Jul; 16(1):79. PubMed ID: 37481608
[TBL] [Abstract] [Full Text] [Related]
2. Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis.
Foran JM; Sun Z; Lai C; Fernandez HF; Cripe LD; Ketterling RP; Racevskis J; Luger SM; Paietta E; Lazarus HM; Zhang Y; Bennett JM; Levine RL; Rowe JM; Litzow MR; Tallman MS
Cancer; 2023 Aug; 129(16):2479-2490. PubMed ID: 37185873
[TBL] [Abstract] [Full Text] [Related]
3. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
[No Abstract] [Full Text] [Related]
4. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
[TBL] [Abstract] [Full Text] [Related]
5. Sensitive Measurement of Minimal Residual Disease in Blood by HAT-PCR.
Latham S; Hughes E; Budgen B; Ross D; Greenwood M; Bradstock K; Dalla-Pozza L; Huang L; Law T; Doculara L; Venn N; Ullah S; Sutton R; Morley AA
J Mol Diagn; 2022 Jun; 24(6):632-641. PubMed ID: 35430373
[TBL] [Abstract] [Full Text] [Related]
6. clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI.
Ma CE; Ghosh S; Leyshon C; Blosser N; Dersch-Mills D; Jupp J; Savoie L; Liew E; Jamani K
Leuk Res; 2021 Dec; 111():106674. PubMed ID: 34333277
[TBL] [Abstract] [Full Text] [Related]
7. The pathological features of leukemic cells infiltrating the renal interstitium in chronic lymphocytic leukemia/small lymphocytic lymphoma from a large single Chinese center.
Wang H; Yu X; Zhang X; Wang S; Zhao M
Diagn Pathol; 2021 Jul; 16(1):59. PubMed ID: 34218814
[TBL] [Abstract] [Full Text] [Related]
8. clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China.
Jia M; Hu BF; Xu XJ; Zhang JY; Li SS; Tang YM
Curr Probl Cancer; 2021 Dec; 45(6):100758. PubMed ID: 34034913
[TBL] [Abstract] [Full Text] [Related]
9. Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Flygt H; Sandin F; Dahlén T; Dremaine A; Lübking A; Markevärn B; Myhr-Eriksson K; Olsson K; Olsson-Strömberg U; Själander A; Söderlund S; Wennström L; Wadenvik H; Stenke L; Höglund M; Richter J
Br J Haematol; 2021 Jun; 193(5):915-921. PubMed ID: 33782950
[TBL] [Abstract] [Full Text] [Related]
10. The factors influencing clinical outcomes after leukapheresis in acute leukaemia.
Lee H; Park S; Yoon JH; Cho BS; Kim HJ; Lee S; Kim DW; Chung NG; Cho B; Kim KB; Yoo J; Jekarl DW; Chae H; Lim J; Kim M; Oh EJ; Kim Y
Sci Rep; 2021 Mar; 11(1):6426. PubMed ID: 33742034
[TBL] [Abstract] [Full Text] [Related]
11. Donor HLA-E Status Associates with Disease-Free Survival and Transplant-Related Mortality after Non In Vivo T Cell-Depleted HSCT for Acute leukemia.
Tsamadou C; Fürst D; Wang T; He N; Lee SJ; Spellman SR; Fleischhauer K; Hsu KC; Paczesny S; Verneris MR; Schrezenmeier H; Mytilineos J
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2357-2365. PubMed ID: 31425756
[TBL] [Abstract] [Full Text] [Related]
12. Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease.
Kinsella FAM; Inman CF; Gudger A; Chan YT; Murray DJ; Zuo J; McIlroy G; Nagra S; Nunnick J; Holder K; Wall K; Griffiths M; Craddock C; Nikolousis E; Moss P; Malladi R
Leuk Res; 2019 Aug; 83():106173. PubMed ID: 31276965
[TBL] [Abstract] [Full Text] [Related]
13.
Bond J; Touzart A; Leprêtre S; Graux C; Bargetzi M; Lhermitte L; Hypolite G; Leguay T; Hicheri Y; Guillerm G; Bilger K; Lhéritier V; Hunault M; Huguet F; Chalandon Y; Ifrah N; Macintyre E; Dombret H; Asnafi V; Boissel N
Haematologica; 2019 Aug; 104(8):1617-1625. PubMed ID: 30655366
[TBL] [Abstract] [Full Text] [Related]
14. Adult onset haemophagocytic lymphohistiocytosis prognosis is affected by underlying disease: analysis of a single-institution series of 174 patients.
Zhang Q; Li L; Zhu L; Zhu J; Yang X; Zhou D; Zheng Y; Zhu M; Xie M; Sun J; Li X; Wu Y; Wei Z; Xie W; Ye X
Swiss Med Wkly; 2018 Sep; 148():w14641. PubMed ID: 30378643
[TBL] [Abstract] [Full Text] [Related]
15. Effects of polymorphic DNA genes involved in BER and caspase pathways on the clinical outcome of myeloproliferative neoplasms under treatment with hydroxyurea.
Azevedo AP; Silva SN; Reichert A; Lima F; Júnior E; Rueff J
Mol Med Rep; 2018 Dec; 18(6):5243-5255. PubMed ID: 30320340
[TBL] [Abstract] [Full Text] [Related]
16. clinical outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes.
Wang L; Devillier R; Wan M; Decroocq J; Tian L; Fürst S; Wang LN; Vey N; Fan X; Blaise D; Hu J
Bone Marrow Transplant; 2019 Mar; 54(3):458-464. PubMed ID: 30082853
[TBL] [Abstract] [Full Text] [Related]
17. Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group.
Roberts KG; Reshmi SC; Harvey RC; Chen IM; Patel K; Stonerock E; Jenkins H; Dai Y; Valentine M; Gu Z; Zhao Y; Zhang J; Payne-Turner D; Devidas M; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Mattano LA; Maloney KW; Carroll WL; Loh ML; Willman CL; Gastier-Foster JM; Mullighan CG; Hunger SP
Blood; 2018 Aug; 132(8):815-824. PubMed ID: 29997224
[TBL] [Abstract] [Full Text] [Related]
18. [Expression and Significance of PD-L1, HSP90 and HSP90α in Serum of Patients with Acute leukemia].
Ma XJ; Zhang FH; Sun L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1384-1389. PubMed ID: 29070112
[TBL] [Abstract] [Full Text] [Related]
19. Fluconazole versus mould-active triazoles for primary antifungal prophylaxis in adult patients with acute lymphoblastic leukemia: clinical outcome and cost-effectiveness analysis.
Wang Y; Xing Y; Chen L; Meng T; Li Y; Xie J; Chen L; Dong Y; Dong W
Int J Hematol; 2018 Feb; 107(2):235-243. PubMed ID: 29027638
[TBL] [Abstract] [Full Text] [Related]
20. HLA-G molecules and clinical outcome in Chronic Myeloid leukemia.
Caocci G; Greco M; Arras M; Cusano R; Orrù S; Martino B; Abruzzese E; Galimberti S; Mulas O; Trucas M; Littera R; Lai S; Carcassi C; La Nasa G
Leuk Res; 2017 Oct; 61():1-5. PubMed ID: 28841441
[TBL] [Abstract] [Full Text] [Related]
[Next]
